10-K: CG Oncology Announces Positive Interim Phase 3 Results for Bladder Cancer Treatment, Plans for Further Expansion

CG Oncology, a late-stage clinical biopharmaceutical company, is advancing its bladder cancer therapeutic, cretostimogene, with promising interim Phase 3 trial results and plans for expanded clinical trials.

Summary

• CG Oncology is developing cretostimogene, a potential bladder-sparing therapeutic for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients unresponsive to Bacillus Calmette Guerin (BCG) therapy.
• The company is evaluating cretostimogene in the Phase 3 BOND-003 trial, with interim data showing a 75.7% complete response (CR) rate at any time in 66 evaluable patients as of October 5, 2023.
• Topline data from the BOND-003 trial is expected by the end of 2024, potentially supporting a Biologics License Application (BLA) submission to the FDA.
• Cretostimogene is also being evaluated in combination with pembrolizumab in the Phase 2 CORE-001 trial, showing an 85% CR rate at any time in 34 evaluable patients as of March 3, 2023.
• The company plans to initiate the Phase 3 PIVOT-006 trial for intermediate-risk NMIBC and the Phase 2 CORE-008 trial for high-risk BCG-exposed and BCG-naive NMIBC.
• CG Oncology aims to address the unmet need in bladder cancer treatment, exacerbated by the ongoing global shortage of BCG therapy.
• The company is building operational capabilities for potential commercialization and leveraging in-house Chemistry, Manufacturing, and Controls (CMC) expertise with an advisory board for scaling production.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for CG Oncology, with strong interim clinical data, a clear development plan, and a focus on addressing a significant unmet need. However, the company's early stage of development, reliance on a single product candidate, and the inherent risks of drug development warrant a slightly cautious sentiment.

Positives

• Cretostimogene has demonstrated promising clinical activity as both a monotherapy and in combination with other therapies.
• Interim results from the BOND-003 trial show a high CR rate and durability of response.
• Cretostimogene has been generally well-tolerated in clinical trials, with mostly low-grade adverse events.
• The drug's administration is similar to BCG therapy, which is familiar to urology practices.
• CG Oncology has a strong CMC expertise and advisory board to support manufacturing and potential commercialization.
• The company is actively pursuing multiple clinical trials across various NMIBC indications, addressing a significant unmet need.
• The company has secured partnerships for development and commercialization in Asia.

Negatives

• The company has a limited operating history and has incurred significant losses since its inception.
• There is no guarantee of regulatory approval or commercial success for cretostimogene.
• The company is dependent on third-party manufacturers for the production of cretostimogene.
• The ongoing global shortage of BCG could impact the perceived need for alternative treatments like cretostimogene if supply improves.
• The company faces substantial competition from other pharmaceutical and biotechnology companies developing bladder cancer therapies.

Risks

• The company is dependent on the success of cretostimogene, which is currently its only product candidate.
• Clinical trials may not yield favorable results or could be delayed due to various factors, including enrollment challenges and adverse events.
• Regulatory approval may not be obtained or could be delayed, and post-approval requirements could be burdensome.
• The company may face challenges in manufacturing cretostimogene at a commercial scale and at an acceptable cost.
• Market acceptance and adoption of cretostimogene by physicians and patients may be limited.
• The company may not be able to obtain or maintain adequate reimbursement from third-party payors.
• The company may face intellectual property challenges or be unable to adequately protect its proprietary technology.
• The company may be subject to product liability claims.
• The company may be unable to attract and retain qualified personnel.
• The company may be impacted by changes in healthcare laws and regulations.
• The company may be impacted by cybersecurity breaches or data privacy issues.
• The company may be impacted by general economic conditions, geopolitical events, or natural disasters.

Future Outlook

The company expects to report topline data from the BOND-003 trial by the end of 2024 and, if successful, believes the trial could serve as the basis for a BLA submission to the FDA. They also anticipate reporting additional durability data from the CORE-001 trial in the first half of 2024. Enrollment for the PIVOT-006 trial is expected to be completed in the first half of 2026, and the CORE-008 trial is expected to be initiated in the second half of 2024.

Industry Context

CG Oncology's focus on NMIBC addresses a significant unmet need in the bladder cancer market, particularly for patients who are unresponsive to BCG therapy. The ongoing global BCG shortage further highlights the demand for alternative treatments. The company's approach of developing cretostimogene as both a monotherapy and in combination with other therapies positions it to potentially capture a significant share of the growing bladder cancer treatment market.

Comparison to Industry Standards

• Compared to the reported 18% CR rate at six months for valrubicin in BCG-refractory patients, cretostimogene demonstrated a 75.7% CR rate at any time in the BOND-003 trial.
• In the KEYNOTE-057 Phase 2 clinical trial, pembrolizumab monotherapy in high-risk BCG-unresponsive NMIBC patients with CIS-stage tumors showed a 41% CR rate at 3 months, declining to 19% at 12 months. Cretostimogene in combination with pembrolizumab in the CORE-001 trial demonstrated a higher CR rate of 85% at any time, with 68% of patients maintaining a CR at 12 months.
• Nadofaragene firadenovec, approved for high-risk BCG-unresponsive NMIBC, showed a 51% CR rate and 24% CR maintenance at 12 months in a Phase 3 trial. Cretostimogene's results in BOND-003 and CORE-001 compare favorably in terms of CR rate and durability.
• ImmunityBio Inc.'s N-803, an IL-15 agonist in combination with BCG, received a complete response letter from the FDA, highlighting the challenges in developing new NMIBC therapies.
• Other companies developing NMIBC treatments include Urogen Pharma, Inc.'s UGN-102, Janssen Pharmaceuticals, Inc.'s TAR-200, and enGene, Inc.'s EG-70, each with different mechanisms of action and administration routes.

Management Changes

Legal Proceedings

• On March 4, 2024, a complaint was filed against the Company in the Superior Court of the State of Delaware by ANI Pharmaceuticals, Inc. seeking a declaratory judgement that an assignment and technology transfer agreement between the Company and ANI, dated November 15, 2010, obligates the Company to pay ANI a royalty on certain 'net sales' of cretostimogene. The Company disputes the allegations and intends to vigorously defend the matter.

Related Party Transactions

• In connection with the ASGL Secondary Sales, Abundant Supply Global Limited sold 3,107,520 shares of Series C redeemable convertible preferred stock to Decheng Capital Global Life Sciences Fund IV, L.P., a greater than 5% stockholder of our company (Decheng Capital Global), 3,107,520 shares of Series C redeemable convertible preferred stock to TCG Crossover Fund I, L.P., 3,107,520 shares of Series C redeemable convertible preferred stock to Longitude Prime Fund, L.P., an entity affiliated with Longitude Venture Partners, a greater than 5% stockholder of our company, (Longitude Prime), an affiliate of Longitude Venture Partners, and an aggregate of 3,107,520 shares of Series C redeemable convertible preferred stock to entities affiliated with Foresite Capital.
• In connection with the ASGL Secondary Sales, we entered into a stock transfer agreement with Abundant Supply Global Limited and each purchaser in January 2024, Abundant Supply Global Limited transferred all of its shares to its affiliate, Unique Diamond Investments Limited.
• In August 2023, Longitude Prime entered into a stock transfer agreement with an entity affiliated with a holder of our capital stock pursuant to which Longitude Prime sold 1,756,323 shares of Series C redeemable convertible preferred stock at a purchase price of $0.9073 per share for an aggregate purchase price of $1,593,511.86 (the August 2023 Longitude Secondary Transaction).
• In July 2023, Longitude Prime entered into a stock transfer agreement with Lepu Holdings Limited pursuant to which Longitude Prime purchased 3,512,646 shares of Series C redeemable convertible preferred stock from Lepu Holdings Limited at a purchase price of $0.9073 per share for an aggregate purchase price of $3,187,023.72 (the July 2023 Longitude Secondary Transaction). Jue Pu, our then-director, was an affiliate of Lepu Holdings Limited at the time of the July 2023 Longitude Secondary Transaction.
• In connection with the August 2023 Longitude Secondary Transaction and the July 2023 Longitude Secondary Transaction, we entered into stock transfer agreements with Longitude Prime and each counterparty.
• In May 2023, Longitude Venture Partners IV, L.P, an entity affiliated with Longitude Venture Partners, entered into a common stock transfer agreement with various holders of capital stock pursuant to which Longitude Venture Partners IV, L.P. purchased 8,873,500 shares of common stock at a purchase price of $0.80055 per share for an aggregate purchase price of $7,103,680.43 (the May 2023 Longitude Secondary Transaction).
• In connection with the May 2023 Longitude Secondary Transaction, we entered into a common stock transfer agreement with Longitude Venture Partners IV, L.P. and each seller pursuant to which, among other things, we waived our right of first refusal to purchase the shares of common stock sold in the transaction.
• In July 2023, Decheng Capital Global entered into a stock transfer agreement with Lepu Holdings Limited pursuant to which Decheng Capital Global purchased 3,512,646 shares of Series C redeemable convertible preferred stock from Lepu Holdings Limited at a purchase price of $0.9073 per share for an aggregate purchase price of $3,187,023.72 (the July 2023 Decheng Secondary Transaction). Jue Pu, our then-director, was an affiliate of Lepu Holdings Limited at the time of the July 2023 Decheng Secondary Transaction.
• In June 2023, Decheng Capital Global entered into a stock transfer agreement with a holder of our capital stock pursuant to which Decheng Capital Global purchased 2,024,725 shares of Series C redeemable convertible preferred stock at a purchase price of $0.91 per share for an aggregate purchase price of $1,842,499.75 (the June 2023 Decheng Secondary Transaction).
• In connection with the July 2023 Decheng Secondary Transaction and the June 2023 Decheng Secondary Transaction, we entered into stock transfer agreements with Decheng Capital Global and each seller.
• In May 2023, Decheng Capital Global entered into common stock transfer agreements with various holders of capital stock pursuant to which Decheng Capital Global purchased 8,873,500 shares of common stock at a purchase price of $0.80055 per share for an aggregate purchase price of $7,103,680.44 (the May 2023 Decheng Secondary Transaction).
• In connection with the May 2023 Decheng Secondary Transaction, we entered into a common stock transfer agreement with Decheng Capital Global and each seller pursuant to which, among other things, we waived our right of first refusal to purchase the shares of common stock sold in the transaction.

Stakeholder Impact

• Shareholders: Potential for significant value creation if cretostimogene is successfully developed and commercialized. Dilution from future capital raises. Stock price volatility.
• Employees: Job creation and opportunities for professional growth as the company expands. Potential for increased workload and pressure to meet development milestones.
• Patients: Potential access to a new and effective bladder-sparing treatment for NMIBC, addressing a significant unmet medical need.
• Suppliers: Increased demand for manufacturing and other services if cretostimogene is commercialized.
• Creditors: Potential for increased debt financing as the company advances its development programs.

Next Steps

• Report topline data from the BOND-003 trial by the end of 2024.
• Potentially submit a BLA to the FDA based on BOND-003 results.
• Report additional durability data from the CORE-001 trial in the first half of 2024.
• Complete enrollment for the PIVOT-006 trial in the first half of 2026.
• Initiate the CORE-008 trial in the second half of 2024.
• Continue to evaluate cretostimogene in combination with other therapies.
• Build operational capabilities for potential commercialization.
• Scale manufacturing efforts to meet potential commercial demand.

Key Dates

Keywords

NMIBC, bladder cancer, immunotherapy, oncolytic virus, cretostimogene, BCG-unresponsive, clinical trials, biopharmaceutical, oncology, intravesical therapy, FDA approval, biologics, urothelial carcinoma, TURBT